COCP
Price
$2.24
Change
+$0.14 (+6.67%)
Updated
Dec 20, 04:59 PM (EDT)
FATE
Price
$1.68
Change
+$0.02 (+1.20%)
Updated
Dec 20 closing price
70 days until earnings call
Ad is loading...

COCP vs FATE

Header iconCOCP vs FATE Comparison
Open Charts COCP vs FATEBanner chart's image
Cocrystal Pharma
Price$2.24
Change+$0.14 (+6.67%)
Volume$117
CapitalizationN/A
Fate Therapeutics
Price$1.68
Change+$0.02 (+1.20%)
Volume$10.14M
CapitalizationN/A
COCP vs FATE Comparison Chart
Loading...
COCP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
FATE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
COCP vs. FATE commentary
Dec 23, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is COCP is a Hold and FATE is a Hold.

COMPARISON
Comparison
Dec 23, 2024
Stock price -- (COCP: $2.25 vs. FATE: $1.68)
Brand notoriety: COCP and FATE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: COCP: 258% vs. FATE: 307%
Market capitalization -- COCP: $22.28M vs. FATE: $192.48M
COCP [@Biotechnology] is valued at $22.28M. FATE’s [@Biotechnology] market capitalization is $192.48M. The market cap for tickers in the [@Biotechnology] industry ranges from $464.4B to $0. The average market capitalization across the [@Biotechnology] industry is $2.57B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

COCP’s FA Score shows that 0 FA rating(s) are green whileFATE’s FA Score has 1 green FA rating(s).

  • COCP’s FA Score: 0 green, 5 red.
  • FATE’s FA Score: 1 green, 4 red.
According to our system of comparison, both COCP and FATE are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

COCP’s TA Score shows that 7 TA indicator(s) are bullish while FATE’s TA Score has 3 bullish TA indicator(s).

  • COCP’s TA Score: 7 bullish, 4 bearish.
  • FATE’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, COCP is a better buy in the short-term than FATE.

Price Growth

COCP (@Biotechnology) experienced а +17.92% price change this week, while FATE (@Biotechnology) price change was -8.20% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.20%. For the same industry, the average monthly price growth was -1.27%, and the average quarterly price growth was +2.17%.

Reported Earning Dates

COCP is expected to report earnings on May 15, 2023.

FATE is expected to report earnings on Mar 03, 2025.

Industries' Descriptions

@Biotechnology (-2.20% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
FATE($192M) has a higher market cap than COCP($22.3M). COCP YTD gains are higher at: 30.647 vs. FATE (-55.080). COCP has higher annual earnings (EBITDA): -20.31M vs. FATE (-177.57M). FATE has more cash in the bank: 297M vs. COCP (13M). COCP has less debt than FATE: COCP (1.88M) vs FATE (99M). FATE has higher revenues than COCP: FATE (13.4M) vs COCP (0).
COCPFATECOCP / FATE
Capitalization22.3M192M12%
EBITDA-20.31M-177.57M11%
Gain YTD30.647-55.080-56%
P/E RatioN/AN/A-
Revenue013.4M-
Total Cash13M297M4%
Total Debt1.88M99M2%
FUNDAMENTALS RATINGS
COCP vs FATE: Fundamental Ratings
COCP
FATE
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
70
Overvalued
18
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9897
PRICE GROWTH RATING
1..100
4594
P/E GROWTH RATING
1..100
99100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

FATE's Valuation (18) in the Biotechnology industry is somewhat better than the same rating for COCP (70) in the Pharmaceuticals Generic industry. This means that FATE’s stock grew somewhat faster than COCP’s over the last 12 months.

FATE's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as COCP (100) in the Pharmaceuticals Generic industry. This means that FATE’s stock grew similarly to COCP’s over the last 12 months.

FATE's SMR Rating (97) in the Biotechnology industry is in the same range as COCP (98) in the Pharmaceuticals Generic industry. This means that FATE’s stock grew similarly to COCP’s over the last 12 months.

COCP's Price Growth Rating (45) in the Pharmaceuticals Generic industry is somewhat better than the same rating for FATE (94) in the Biotechnology industry. This means that COCP’s stock grew somewhat faster than FATE’s over the last 12 months.

COCP's P/E Growth Rating (99) in the Pharmaceuticals Generic industry is in the same range as FATE (100) in the Biotechnology industry. This means that COCP’s stock grew similarly to FATE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
COCPFATE
RSI
ODDS (%)
Bearish Trend 5 days ago
90%
Bullish Trend 4 days ago
88%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
83%
Bullish Trend 3 days ago
80%
Momentum
ODDS (%)
Bullish Trend 3 days ago
84%
Bearish Trend 3 days ago
87%
MACD
ODDS (%)
Bullish Trend 3 days ago
81%
Bearish Trend 3 days ago
88%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
85%
Bearish Trend 3 days ago
89%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
86%
Bearish Trend 3 days ago
90%
Advances
ODDS (%)
Bullish Trend 7 days ago
83%
Bullish Trend 14 days ago
86%
Declines
ODDS (%)
Bearish Trend 11 days ago
88%
Bearish Trend 4 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
84%
Aroon
ODDS (%)
Bearish Trend 6 days ago
89%
Bearish Trend 3 days ago
90%
View a ticker or compare two or three
Ad is loading...
COCP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
FATE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
DTSS2.120.09
+4.43%
Datasea
REPL12.490.48
+4.00%
Replimune Group
HUBB426.802.25
+0.53%
Hubbell
CPA88.870.27
+0.30%
Copa Holdings SA
OOMA14.37-0.04
-0.28%
Ooma

COCP and

Correlation & Price change

A.I.dvisor indicates that over the last year, COCP has been loosely correlated with FATE. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if COCP jumps, then FATE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To COCP
1D Price
Change %
COCP100%
+7.14%
FATE - COCP
34%
Loosely correlated
+1.20%
VKTX - COCP
31%
Poorly correlated
+1.83%
BYSI - COCP
28%
Poorly correlated
+2.58%
OMER - COCP
27%
Poorly correlated
+0.68%
CYTK - COCP
27%
Poorly correlated
+4.56%
More